Pertuzumab growth inhibition of the HER3-positive pancreatic cancer cell line BxPC-3 was significantly increased following stimulation with NRG1β1 (60% inhibition with neuregulin stimulation versus 35% without it) (Figure 2B). Here, ERBB3 is linked to familial pancreatic carcinoma.